secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001193805-22-000752
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q1 net loss $51.2M ($1.94/share); ARCT-154 booster shows 54-fold Omicron BA.1 response
--------------------------------------------------------------------------------

- Q1 2022 revenue $5.2M (up from $2.1M YoY); operating expenses $55.6M; net loss $51.2M.
- Cash $319.7M at March 31, 2022; expected to fund operations into late 2023.
- ARCT-154 booster data: 54-fold and 46-fold GMFR against Omicron BA.1 and BA.2 at Day 29.
- Primary vaccine efficacy 95.3% against severe COVID-19; 55% overall; 98.4% seroconversion.
- ARCT-810 Phase 2 OTC deficiency trial to start Q2 2022; ARCT-032 cystic fibrosis CTA filing on track for Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522000752/0001193805-22-000752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522000752/e621634_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-22-000752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer